CNM Publications 2009 to Present

Selected Publications

Found 106 results
Author Title [ Type(Desc)] Year
Journal Article
Wang J, Liu Y, Teesalu T, Sugahara KN, Kotamrajua VRamana, Adams JD, Ferguson BS, Gong Q, Oh SSoo, Csordas AT et al..  2011.  Selection of phage-displayed peptides on live adherent cells in microfluidic channels.. Proc Natl Acad Sci U S A. 108(17):6909-14.
Sánchez-Martín D, Sørensen MDræby, Lykkemark S, Sanz L, Kristensen P, Ruoslahti E, Álvarez-Vallina L.  2015.  Selection strategies for anticancer antibody discovery: searching off the beaten path.. Trends Biotechnol. 33(5):292-301.
Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS.  2012.  Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.. J Control Release. 161(3):804-12.
Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M.  2012.  Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels.. Cancer Cell. 22(2):235-49.
Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, Peters D, Roth L, M Gagnon KJ, Ferrara KW et al..  2011.  Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice.. Proc Natl Acad Sci U S A. 108(17):7154-9.
Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VRamana, Basu S et al..  2013.  Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.. Cancer Res. 73(23):6987-97.
Zhang Y, Yang M, Park J-H, Singelyn J, Ma H, Sailor MJ, Ruoslahti E, Ozkan M, Ozkan C.  2009.  A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles.. Small. 5(17):1990-6.
Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Marth JD, Bertozzi CR, Hart GW, Etzler ME.  2009.  Symbol nomenclature for glycan representation.. Proteomics. 9(24):5398-9.
Ewert KK, Kotamraju VRamana, Majzoub RN, Steffes VM, Wonder EA, Teesalu T, Ruoslahti E, Safinya CR.  2016.  Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes.. Bioorg Med Chem Lett. 26(6):1618-23.
Kolhar P, Kotamraju VRamana, Hikita ST, Clegg DO, Ruoslahti E.  2010.  Synthetic surfaces for human embryonic stem cell culture.. J Biotechnol. 146(3):143-6.
Park J-H, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, Ruoslahti E, Bhatia SN, Sailor MJ.  2009.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.. Small. 5(6):694-700.
Järvinen TAH, Ruoslahti E.  2013.  Targeted Antiscarring Therapy for Tissue Injuries.. Adv Wound Care (New Rochelle). 2(2):50-54.
Agemy L, Friedmann-Morvinski D, Kotamraju VRamana, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM, Ruoslahti E.  2011.  Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.. Proc Natl Acad Sci U S A. 108(42):17450-5.
Willmore A-MA, Simón-Gracia L, Toome K, Paiste P, Kotamraju VRamana, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.  2016.  Targeted silver nanoparticles for ratiometric cell phenotyping.. Nanoscale. 8(17):9096-101.
Ren Y, Cheung HWing, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF et al..  2012.  Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.. Sci Transl Med. 4(147):147ra112.
Peters D, Kastantin M, Kotamraju VRamana, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E.  2009.  Targeting atherosclerosis by using modular, multifunctional micelles.. Proc Natl Acad Sci U S A. 106(24):9815-9.
Karmali PPrakash, Kotamraju VRamana, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E.  2009.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors.. Nanomedicine. 5(1):73-82.
Ruoslahti E, Bhatia SN, Sailor MJ.  2010.  Targeting of drugs and nanoparticles to tumors.. J Cell Biol. 188(6):759-68.
Hunt H, Simón-Gracia L, Tobi A, Kotamraju VRamana, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.  2017.  Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.. J Control Release. 260:142-153.
Järvinen TAH, Ruoslahti E.  2010.  Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice.. Proc Natl Acad Sci U S A. 107(50):21671-6.
Sugahara KN, Teesalu T, Karmali PPrakash, Kotamraju VRamana, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.  2009.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.. Cancer Cell. 16(6):510-20.
Brunquell C, Biliran H, Jennings S, Ireland SKale, Chen R, Ruoslahti E.  2012.  TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.. Mol Cancer Res. 10(11):1482-95.
King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, Agemy L, Teesalu T, Glazier JD, Cellesi F, Tirelli N et al..  2016.  Tumor-homing peptides as tools for targeted delivery of payloads to the placenta.. Sci Adv. 2(5):e1600349.
Sugahara KN, Braun GB, de Mendoza THurtado, Kotamraju VRamana, French RP, Lowy AM, Teesalu T, Ruoslahti E.  2015.  Tumor-penetrating iRGD peptide inhibits metastasis.. Mol Cancer Ther. 14(1):120-8.
Sharma S, Kotamraju VRamana, Mölder T, Tobi A, Teesalu T, Ruoslahti E.  2017.  Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.. Nano Lett. 17(3):1356-1364.